CoChat

The Brave New World of Function-Promoting Anabolic Therapies: Testosterone and Frailty

Open access
Bhasin, Shalender · 2010 · The Journal of Clinical Endocrinology & Metabolism
Cited by 33

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Physical function is an excellent marker of an individual’s health (1). Limitations in physical function are an important public health problem because of their high prevalence and their association with adverse health outcomes, including the increased risk of disability, poor quality of life, hospitalization, and mortality (2, 3). In the USA alone, 12–14% of the noninstitutionalized population—approximately 35–38 million people—have a disability due to a chronic health condition (4). For people over age 65 yr, 35 to 40% experience activity limitations or disability. Because the U.S. population is aging, the percentage of population aged 65 yr or over will increase from 12% in 2000 to 20% in 2030—to more than 69 million. The number of people 85 or older is expected to grow from 3 million (2.1%) to 6.2 million (3.4%) in the United States alone. The majority of individuals who reach this age will experience some limitation in function (4, 5). The costs of support services, lost productivity associated with disabling conditions, and the impact of disability on an individual’s quality of life will have enormous societal consequences (6). Currently, the practicing physicians have few therapeutic choices for the treatment of older individuals with functional limitations and physical disability. Exercise, physical rehabilitation, and behavioral modalities have had limited impact at a population level. Therefore, there is growing need for developing pharmacological function promoting therapies for the treatment of functional limitations. It has become apparent that a small number of intersecting signaling pathways are crucial for regulating muscle growth through their effects on ribosomal protein translation (AkT/mammalian target of rapamycin pathway), mesenchymal progenitor cell differentiation (Wnt and Smad signaling), and muscle protein degradation (ubiquitin-proteasome pathway and the FoXo family of transcription factors). Pharmacophores that selectively modulate these signaling pathways, such as androgens, myostatin antagonists, and GH/IGF-I mimetics are being explored for their potential as function-promoting anabolic therapies; of these, androgens are the farthest along in development. The idea that androgens have anabolic effects on the skeletal muscle is not new. Athletes and recreational body builders who abuse androgens do so because of the widely held perception that androgens increase muscle mass, muscle strength, and athletic performance. However, systematic investigations of androgens as function-promoting therapies have been limited largely to the past 15 yr (7). Epidemiological studies have shown that circulating testosterone levels are associated with skeletal muscle mass, muscle strength, and self-reported as well as performance-based measures of physical function (8–10). Cawthon et al. (11) reported in a recent issue of the Journal that low levels of bioavailable testosterone in men participating in the Osteoporotic Fractures in Men Study (MrOS) were associated independently with worse frailty status. In longitudinal analysis, the men in the lowest quartile of bioavailable testosterone levels had approximately 1.5-fold higher odds of greater frailty status 4.1 yr later (11). However, neither total nor free testosterone levels were associated with frailty status. Mohr et al. (12) in a separate analysis of the data from the Massachusetts Male Aging Study (MMAS) also found no significant association of total or free testosterone levels with overall frailty status. However, in the MMAS, total testosterone levels were associated with some frailty components—grip strength and physical activity—but not with other components such as exhaustion, slow walking, or weight loss (12). In light of the known effects of testosterone on muscle mass and strength, it is not surprising that testosterone levels would be associated with frailty components that are more tightly linked to skeletal muscle mass and strength. Undoubtedly, frailty is a heterogeneous construct, and not all of its components share a common biological or pathophysiological basis or have the same prognostic significance (13). In this issue of the Journal, Srinivas-Shankar et al. (14) report the results of the first randomized clinical trial of the effects of testosterone therapy in older men with one or more components of the frailty syndrome, total testosterone less than 12 nmol/liter, or free testosterone less than 250 pmol/liter. The study had several features of good clinical trial design: randomization, blinding of subjects and investigators, parallel group design, and inclusion of a placebo group as the reference for comparison (14). Unlike some other important studies that did not achieve robust increments in testosterone concentrations (15, 16), Srinivas-Shankar et al. (14) adjusted the testosterone dose to achieve testosterone concentrations in the target range. Testosterone therapy was associated with greater improvements in isokineti

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2009-2550

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 33

Metadata

Authors
Bhasin, S.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2010-02-01
Volume
95
Issue
2
Pages
509-511
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2074941721
Cited by
33
References
9
FWCI
3.52
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Brave New World of Function-Promoting Anabolic Therapies: Testosterone and Frailty. https://app.cochat.ai/papers/10.1210/jc.2009-2550
The paper
Bhasin, S. (2010). The Brave New World of Function-Promoting Anabolic Therapies: Testosterone and Frailty. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2009-2550

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.